China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations
China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...
SAMR
China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...
Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China,...
NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time
The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...
National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector
An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...
National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector
The emergency response department of the National Health Commission (NHC) has released a notification signaling...
SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements
The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...
Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector
The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...
China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices
The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...
China’s New Internet Advertising Regulations Impact Pharmaceutical Sector
The State Administration for Market Regulation has released the latest version of the “Measures for...
Tianjin Tianyao Fined for Anti-Monopoly Violations in Carmustine Sales
China-based Tianjin Tianyao Pharmaceutical Co., Ltd (SHA: 600488) has been fined RMB 27.72 million (USD...
SAMR Issues New Rules for Online Drug Sales in China
China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...